NCT06313528CompletedPhase 1
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction
Source: ClinicalTrials.gov · Last updated 23 Sept 2025
Brief summary (registry, in English)
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 85 (actual)
- First submitted
- 11 Mar 2024
- Start date
- 20 Mar 2024
- Primary completion date
- 26 Aug 2025
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT06313528
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 85
- From 20 Mar 2024 to the primary completion date, 26 Aug 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study
- Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty
- Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity
- Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure
- History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior
- Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain
Other illness
- Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state
- Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2
- Acute or chronic hepatitis
- History of chronic or acute pancreatitis
- Clinically significant multiple or severe drug allergies
- History of substance use disorder
Other
- Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia
Who the study is looking for
- BMI greater than 30 kg/m2
- History of at least 1 self-reported unsuccessful dietary effort to reduce body weight
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pennington Biomedical Research Center Coordinator of this site? Confirm its status | Baton Rouge | United States | Unknown status |
| Columbia University Irving Medical Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| AdventHealth Orlando Coordinator of this site? Confirm its status | Orlando | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.